本文源自：财华网 【财华社讯】复星医药(600196.SH;02196.HK)公布，控股子公司复星医药产业与生物技术公司Clavis Bio 达成战略合作，双方将基于由Clavis Bio名的前沿靶点共同开发创新疗法。ClavisBio系AditumBio旗下基 金为本次合作设立的全资控股子公司。 如本次合作中的某一合作项目获ClavisBio行使选择权，就该单一合作项目而言，复星医药将可获得至多 3.625亿美元付款，包括不可退还的行权费、开发注册里程碑付款及销售里程碑付款，并可基于该合作 项目所涉产品于许可区域內的净销售额达成情况收取约定百分比例的特许权使用费。 根据协议，双方将在约定的5年合作期限內，基于ClavisBio提名的靶点(每年至多4个)共同选定并推进针 对获选靶点化合物的临床前开发。针对每个合作项目，ClavisBio享有在除中国內地及港澳地区以外的全 球区域內进行开发、生产及商业化的独家许可选择权。无论ClavisBio是否行使该项全球许可选择权，复 星医药均保留在中国內地及港澳地区进行独家开发、生产和商业化的权利。 ...

财务数据显示，截至2025年09月30日，康乃德生物收入总额6.4万美元，同比减少99.75%；归母净利 润-4037.1万美元，同比减少500.58%。 资料显示，康乃德生物医药控股有限公司是一家拥有临床阶段产品、全球化布局的生物医药公司,通过 自主研发的T细胞功能调节平台开发创新疗法,从而改善炎症性免疫疾病患者的生活品质。 据交易所数据显示，12月15日，康乃德生物(CNTB)开盘上涨2.88%，截至22:30，报2.5美元/股，成交 28.62万美元，总市值1.40亿美元。 作者：行情君 本文源自：市场资讯 ...

Core Points - AstraZeneca signed a cooperation agreement with the Qingdao High-tech Industrial Development Zone Management Committee, announcing an additional investment of approximately $136 million to expand production capacity in Qingdao [1] - The Qingdao project will utilize energy-saving technologies to achieve near-zero carbon operations [1] Company Operations - AstraZeneca has three major production bases in China located in Wuxi, Taizhou, and Qingdao [1] - The Wuxi base has achieved 100% renewable energy usage and is the first in the industry to implement innovative clean heating solutions, receiving carbon neutrality certification [1] - The Taizhou base has reduced carbon emissions by 97.5% compared to 2015 [1] - The Qingdao base, currently under construction, is expected to achieve near-zero carbon operations upon commencement of production [1] Industry Engagement - This year marks AstraZeneca's eighth participation in the China International Import Expo (CIIE), showcasing innovative therapies across multiple disease areas [1] - Over the past seven years, AstraZeneca has introduced 18 "CIIE treasures," covering respiratory, renal, digestive, rare diseases, autoimmune diseases, and oncology, providing more treatment options for patients [1] - AstraZeneca's Global Executive Vice President and Head of International Business, Iskra Reic, emphasized the company's commitment to deepening engagement in China and contributing to the country's role as a global hub for healthcare innovation [1]

Group 1 - The core viewpoint of the article highlights the successful debut of Jinfang Pharmaceutical on the Hong Kong Stock Exchange, with a significant stock price increase of 106.5% on its first trading day, closing at HKD 42.1 per share and achieving a total market capitalization of HKD 15.03 billion [1] - Jinfang Pharmaceutical, established in 2017, focuses on the development of innovative therapies for oncology, autoimmune, and inflammatory diseases, with a pipeline that includes 8 candidate products, 5 of which are in clinical development [1] - Financial data indicates that the company's revenues for the years 2023-2024 and the first four months of 2025 were HKD 73.734 million, HKD 105 million, and HKD 82.149 million respectively, while the losses for the same periods were HKD 508 million, HKD 678 million, and HKD 66.624 million [1]

Core Viewpoint - Conade Biopharma (CNTB) experienced a 5.06% increase in stock price, reaching $1.818 per share, with a total market capitalization of $101 million as of August 22 [1] Financial Performance - As of June 30, 2025, Conade Biopharma reported total revenue of $48,000, representing a 99.8% year-over-year decrease [1] - The company recorded a net loss attributable to shareholders of $23.171 million, which is a 476.52% year-over-year decline [1] Company Overview - Conade Biopharma Holdings Limited is a biopharmaceutical company with clinical-stage products and a global presence, focusing on developing innovative therapies through its proprietary T-cell function modulation platform to improve the quality of life for patients with inflammatory immune diseases [1]

本文源自：金融界 作者：行情君 8月5日，君实生物(01877)盘中上涨32.83%，截至15:54，报31.96元/股，成交11.06亿元。 上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法，特别是在肿瘤免疫疗 法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创 新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。 截至2025年一季报，君实生物营业总收入5.01亿元、净利润-2.35亿元。 ...